Loading…
Develops Haduvio, an oral therapy for chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough.
Develops Haduvio, an oral therapy for chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough.
Has no product to sell, so it is funded by money raised from investors, and spending on trials sets its cash needs. Everything rests on whether the drug, nalbuphine in an extended-release tablet, shows benefit in cough studies and wins approval.
Moat: none (IP / patents). Addresses an underserved chronic cough market with no approved US treatments, but is still clinical-stage.
Headquarters: New Haven, Connecticut, US · Founded: 2009 · Employees: 34
Size Trevi Therapeutics (TRVI) is a United States Health Care company (Biotechnology) with a market value of $2.04B, the 1777th largest of 3,117 United States companies the cockpit tracks. Shares closed at $14.33 on 6 Nov 2026.
Performance Over six months the shares fell 1.2%, against +20.0% for the median peer and -1.1% for the United States market (cap-weighted) — 7th lowest of 21 in its peer set.
Short interest Short interest is 11.2% of the free float (15 Oct 2026).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$137,000 | -$132,000 | -$147,000 | -$123,000 | -$43,000 |
| EBITDA | -$59.4M | -$49.2M | -$51.4M | -$33.8M | -$29.9M |
| Net income | -$51.1M | -$42.8M | -$47.9M | -$29.1M | -$29.2M |
| Free cash flow | n/a | -$42.1M | -$38.3M | -$31.8M | -$28.3M |
| Capital expenditure | $0 | $12,000 | $35,000 | $137,000 | $159,000 |
| Total debt | $605,000 | $753,000 | $1.03M | $1.34M | $9.18M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Trevi Therapeutics TRVI | $2.04B | -1% | n/a | n/a | n/a | n/a |
| Merck & MRK | $362B | +33% | +5% | 18% | 5.4× | 4.1% |
| Bayer BAYN.DE | $61.2B | +46% | -2% | 14% | 2.0× | 2.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TRVI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.7% | +1.3% | 5th highest of 21 |
| 6-month return | -1.2% | +20.0% | 7th lowest of 21 |
| Distance from 52-week high | -29.1% | -27.0% | 10th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Trevi Therapeutics TRVI | United States | $2.04B | -1% | n/a | n/a | n/a | n/a | n/a |
| Replimune REPL | United States | $2.05B | +547% | n/a | n/a | n/a | n/a | n/a |
| Vir Biotechnology VIR | United States | $2.07B | +34% | +1,496% | -92% | 5.4× | n/a | n/a |
| First Tracks Biotherapeutics TRAX | United States | $2.01B | +145% | n/a | n/a | n/a | n/a | n/a |
| GemPharmatech 688046.SS | China | $2.01B | +59% | +25% | 22% | 13.3× | 35.7% | +24.8% |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $2.11B | -9% | -9% | 6% | 5.6× | 25.3% | +3.4% |
| Hitgen 688222.SS | China | $2.12B | +23% | +42% | 27% | 19.1× | 38.7% | +16.8% |
| BioCryst Pharmaceuticals BCRX | United States | $1.97B | -11% | +60% | 42% | 2.5× | -10.6% | +117.9% |
| Maravai Lifesciences MRVI | United States | $1.95B | +108% | -3% | -13% | 9.3× | n/a | n/a |
| Alamar Biosciences ALMR | United States | $1.95B | +17% | +195% | -42% | 23.6× | n/a | n/a |
| Vera Therapeutics VERA | United States | $2.15B | -18% | n/a | n/a | n/a | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.19B | +25% | +259% | 60% | n/a | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $2.19B | +6% | +56% | -725% | 25.1× | n/a | n/a |
| Alvotech ALVO | United States | $1.90B | +49% | -12% | 9% | 6.5× | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.21B | +8% | +21% | 45% | 5.5× | 5.1% | +41.4% |
| Immunome IMNM | United States | $2.21B | -17% | -100% | n/a | n/a | n/a | n/a |
| SKBS 302440.KS | South Korea | $2.22B | -11% | +23% | -25% | 4.5× | n/a | n/a |
| Sinocelltech 688520.SS | China | $2.25B | -23% | -40% | -75% | 15.6× | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +41% | +8% | 19% | 4.9× | 12.5% | +44.5% |
| Zenas BioPharma ZBIO | United States | $1.84B | +44% | -93% | -27,390% | 1,588.4× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.83B | 0% | +556% | -43% | 15.2× | n/a | n/a |